Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 101–200 of 1,000
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 148
Genomic insights into the causes of type 2 diabetes
Langenberg, C., & Lotta, L. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31132-2 · Cited by 149
Molecular Property Design: Does Everyone Get It?
Leeson, P. D., & Young, R. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00157 · Cited by 143
Progress and promise in understanding the genetic basis of common diseases
Price, A. L., Spencer, C. C. A., & Donnelly, P. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2015.1684 · Cited by 147
A review of biomedical datasets relating to drug discovery: a knowledge graph perspective
Bonner, S., Barrett, I. P., Ye, C., Swiers, R., Engkvist, O., Bender, A., Hoyt, C. T., & Hamilton, W. L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac404 · Cited by 196
“Whilst a full review of the area is beyond the scope of this work, interested readers are referred to relevant reviews [139, 29, 96] and here we instead give a high-level overview of key concepts for machine learning practitioners, giving context for subsequent discussion of relevant knowledge graph resources.”
BackgroundKnopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R., Maruff, P., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 143
“This move of improving diagnostic accuracy and ensuring presence of pathology is intuitive, but also by industry drug development standards, considered as crucial for improving probability of success and improving the probability to demonstrate clinical benefit [87].”
BackgroundLauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Translational precision medicine: an industry perspective
Hartl, D., Luca, V. D., Kostikova, A., Laramie, J. M., Kennedy, S., Ferrero, E., Siegel, R. W., Fink, M., Ahmed, S., Millholland, J. M., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02910-6 · Cited by 186
“From a drug development perspective, the longitudinal analysis of the AstraZeneca small molecule portfolio (five-dimensional (5R) framework) demonstrated that the inclusion of biomarkers into early drug development (Ph2 studies) was associated with active or successful projects in contrast to comparable projects witho…”
BackgroundFang, J., Zhang, P., Wang, Q., Chiang, C.-W., Zhou, Y., Hou, Y., Xu, J., Chen, R., Zhang, B., Lewis, S. J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00951-z · Cited by 140
“Broadly in disease, drug targets with genetic support have carried a high success rate among U.S. Food and Drug Administration (FDA)- approved therapies [13, 14].”
BackgroundReactive Metabolites: Current and Emerging Risk and Hazard Assessments
Thompson, R. A., Isin, E. M., Ogese, M. O., Mettetal, J. T., & Williams, D. P. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00410 · Cited by 140
Tissue chips – innovative tools for drug development and disease modeling
Low, L. A., & Tagle, D. A. (2017) · Lab on a Chip · doi:10.1039/c7lc00462a · Cited by 140
Designing stem cell niches for differentiation and self-renewal
Donnelly, H., Salmeron-Sanchez, M., & Dalby, M. J. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0388 · Cited by 139
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
“Altogether, this has led to the proposal that the better the quality of non-clinical safety profiles, the higher the success rates for moving phase II upward (Cook et al., 2014; Walker et al., 2020).”
BackgroundMendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 133
Nuccio, M. L., Paul, M. J., Bate, N. J., Cohn, J., & Cutler, S. R. (2018) · Plant Science · doi:10.1016/j.plantsci.2018.01.020 · Cited by 153
“The limitations of a discovery pipeline approach do not only apply to agriculture, similar issues affected success in pharmaceutical discovery [36], particularly in translation from early discovery to clinical trials (the so-called Valley of Death) [37].”
BackgroundComparison of minipig, dog, monkey and human drug metabolism and disposition
Dalgaard, L. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2014.12.005 · Cited by 132
In silico prediction of novel therapeutic targets using gene–disease association data
Ferrero, E., Dunham, I., & Sanseau, P. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1285-6 · Cited by 130
“However, it is important to emphasise that such an approach could already have a significant impact in drug development considering the current success rates across the pharmaceutical industry [3, 4].”
BackgroundInfluentialImportance of Drug Pharmacokinetics at the Site of Action
Rizk, M., Zou, L., Savic, R., & Dooley, K. (2017) · Clinical and Translational Science · doi:10.1111/cts.12448 · Cited by 131
Coimbra, J. T. S., Feghali, R., Ribeiro, R. P., Ramos, M. J., & Fernandes, P. A. (2021) · RSC Advances · doi:10.1039/d0ra09995c · Cited by 155
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 134
Archer, C. R., Sargeant, R., Basak, J., Pilling, J., Barnes, J. R., & Pointon, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28393-y · Cited by 126
Current Advances on 3D‐Bioprinted Liver Tissue Models
Ma, L., Wu, Y., Li, Y., Aazmi, A., Zhou, H., Zhang, B., & Yang, H. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001517 · Cited by 123
Organs-on-chips: Progress, challenges, and future directions
Low, L. A., & Tagle, D. A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217700523 · Cited by 125
Using artificial intelligence methods to speed up drug discovery
Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1621284 · Cited by 124
“at evaluating the candidate drug’s efficacy and safety in patient populations [2].”
BackgroundDavies, M., Jones, R. D. O., Grime, K., Jansson-Löfmark, R., Fretland, A. J., Winiwarter, S., Morgan, P., & McGinnity, D. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.004 · Cited by 123
Self-citation“Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.”
Corlăteanu, A., Mendez, Y. H., Wang, Y., Garnica, R. D. J. A., Botnaru, V., & Siafakas, N. M. (2019) · Pulmonology · doi:10.1016/j.pulmoe.2019.10.006 · Cited by 147
Sala, L., Bellin, M., & Mummery, C. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13577 · Cited by 121
“Cardiotoxicity caused by electrical disruption A second form of cardiotoxicity, commonly evident in the early phases of drug discovery, is the acute and direct, detrimental effect of drugs on the electrophysiological properties of CMs (Cook et al., 2014).”
BackgroundImmune cell screening of a nanoparticle library improves atherosclerosis therapy
Tang, J., Baxter, S., Menon, A., Alaarg, A., Sanchez-Gaytan, B. L., Fay, F., Zhao, Y., Ouimet, M., Braza, M. S., Longo, V. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609629113 · Cited by 117
“Most experimental small molecules for atherosclerosis, however, failed clinical trials due to their unfavorable toxicity profiles, generally caused by high accumulation in nontargeted tissues or in nontargeted cells within the targeted tissues (39).”
BackgroundFactors Affecting the Pharmacology of Antibody–Drug Conjugates
Lucas, A., Price, L., Schorzman, A., Storrie, M., Piscitelli, J., Razo, J., & Zamboni, W. (2018) · Antibodies · doi:10.3390/antib7010010 · Cited by 120
“Improved high throughput methods would be of particular benefit, as it is suggested that ~15% of phase I studies fail due to unfavorable PK and PD properties [151].”
BackgroundToday’s Challenges to De-Risk and Predict Drug Safety in Human “Mind-the-Gap”
Weaver, R. J., & Valentin, J.-P. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfy270 · Cited by 119
Emerging technologies and their impact on regulatory science
Anklam, E., Bahl, M. I., Ball, R., Beger, R. D., Cohen, J. E., Fitzpatrick, S., Girard, P., Halamoda‐Kenzaoui, B., Hinton, D., Hirose, A., et al. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211052280 · Cited by 148
Liu, X., Ye, K., van Vlijmen, H., Emmerich, M., IJzerman, A. P., & van Westen, G. J. P. (2021) · Journal of Cheminformatics · doi:10.1186/s13321-021-00561-9 · Cited by 146
“Side effects of drugs caused by binding to unexpected offtargets are one of the main reasons of clinical failure of drug candidates and even withdrawal of FDA-approved novel drugs [3, 4].”
BackgroundPredictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
Yamaguchi, S., Kaneko, M., & Narukawa, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12980 · Cited by 143
Bernetti, M., Cavalli, A., & Mollica, L. (2017) · MedChemComm · doi:10.1039/c6md00581k · Cited by 120
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 121
Human Organoids for Predictive Toxicology Research and Drug Development
Matsui, T., & Shinozawa, T. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767621 · Cited by 109
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
“Demonstration of target engagement early in the development process makes it more likely—without proving—that clinical benefits may follow long-term therapy [16].”
BackgroundPrediction of intracellular exposure bridges the gap between target- and cell-based drug discovery
Mateus, A., Gordon, L. J., Wayne, G. J., Almqvist, H., Axelsson, H., Seashore-Ludlow, B., Treyer, A., Matsson, P., Lundbäck, T., West, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701848114 · Cited by 103
“The amount of the unbound species in each compartment (Au,comp) was the sum of the amounts of uncharged (Au,uncharged) and charged (Au,charged) species: Au,comp = Cu,uncharged +Cu,charged ·Vcomp, [6] where Vcomp is the volume of the relevant compartment.”
Luo, Y., Chen, S., Zhou, J., Chen, J., Tian, L., Gao, W., Zhang, Y., Ma, A., Li, L., & Zhou, Z. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.02.004 · Cited by 106
Toxicity testing in the 21st century beyond environmental chemicals
Rovida, C. (2015) · ALTEX · doi:10.14573/altex.1506201 · Cited by 106
“On the other hand, detecting target organ toxicity continues to be a challenge (Cook et al., 2014; Horner et al., 2014).”
BackgroundResultEmerging role of the P2X7-NLRP3-IL1β pathway in mood disorders
Bhattacharya, A., & Jones, D. N. C. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.08.015 · Cited by 105
Patlewicz, G., & Fitzpatrick, J. M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00388 · Cited by 104
Yildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 117
“, 2015), or more systematic portfolio review to systematically challenge development candidates (Cook et al., 2014).”
BackgroundPhenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09407-3 · Cited by 101
Advancement of Sensor Integrated Organ-on-Chip Devices
Clarke, G. A., Hartse, B. X., Asli, A. E. N., Taghavimehr, M., Hashemi, N., Shirsavar, M. A., Montazami, R., Alimoradi, N., Nasirian, V., Ouedraogo, L. J. G., et al. (2021) · Sensors · doi:10.3390/s21041367 · Cited by 115
“described a five framework focus for creating and pursuing a successful project, and within their review, it was seen that a vast majority of toxicological studies failed [74].”
BackgroundDisciplined approach to drug discovery and early development
Plenge, R. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2608 · Cited by 101
Edmondson, S. D., Zhu, C. G., Kar, N. F., Salvo, J. D., Nagabukuro, H., Sacre-Salem, B., Dingley, K. H., Berger, R., Goble, S. D., Morriello, G. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01372 · Cited by 108
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
Gonçalves, E., Segura‐Cabrera, A., Pacini, C., Picco, G., Behan, F. M., Jaaks, P., Coker, E. A., van der Meer, D., Barthorpe, A., Lightfoot, H., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199405 · Cited by 101
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Reichel, A., & Lienau, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_26 · Cited by 116
The impact of in silico screening in the discovery of novel and safer drug candidates
Rognan, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.034 · Cited by 119
Target Engagement in Lead Generation
Durham, T. B., & Blanco, M.-J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.076 · Cited by 97
Ruscitti, F., Ravanetti, F., Essers, J., Ridwan, Y. R., Belenkov, S., Vos, W. G., Ferreira, F., KleinJan, A., van Heijningen, P., Holsbeke, C. S. V., et al. (2017) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-017-0089-0 · Cited by 106
Trials and Terminations: Learning from Competitors’ R&D Failures
Krieger, J. (2021) · Management Science · doi:10.1287/mnsc.2020.3775 · Cited by 123
Introducing an automated high content confocal imaging approach for Organs-on-Chips
Peel, S., Corrigan, A. M., Ehrhardt, B., Jang, K.-J., Caetano-Pinto, P., Boeckeler, M., Rubins, J. E., Kodella, K., Petropolis, D. B., Ronxhi, J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00829a · Cited by 98
The promises of quantitative systems pharmacology modelling for drug development
Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Le Novère, N. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.002 · Cited by 97
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
Guo, S.-W., & Groothuis, P. G. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy020 · Cited by 95
“Drug developers at AstraZeneca took a closer look at what stage the projects fail, and why, and it was evident that the project failure rate is highest in the Phase IIa proof of concept phase (Cook et al., 2014).”
BackgroundThe ORMDL3 Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation
Zhang, Y., Willis‐Owen, S. A. G., Spiegel, S., Lloyd, C. M., Moffatt, M. F., & Cookson, W. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0438oc · Cited by 106
Sutherland, J. J., Webster, Y., Willy, J. A., Searfoss, G. H., Goldstein, K. M., Irizarry, A. R., Hall, D. G., & Stevens, J. L. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.17 · Cited by 97
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
Burt, T., Yoshida, K. J., Lappin, G., Vuong, L. T., John, C. S., de Wildt, S. N., Sugiyama, Y., & Rowland, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12390 · Cited by 100
ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish
Cornet, C., Calzolari, S., Prieto, R. M., Dyballa, S., van Doornmalen, E. J. P., Rutjes, H., Savy, T., D’Amico, D., & Terriente, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040864 · Cited by 102
Odawara, A., Matsuda, N., Ishibashi, Y., Yokoi, R., & Suzuki, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-28835-7 · Cited by 94
A 3D Human Airway Model Enables Prediction of Respiratory Toxicity of Inhaled Drugs In Vitro
Balogh Sivars, K., Sivars, U., Hornberg, E., Zhang, H., Brändén, L., Bonfante, R., Huang, S., Constant, S., Robinson, I., Betts, C. J., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx255 · Cited by 92
Walker, P. A., Ryder, S., Lavado, A., Dilworth, C., & Riley, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02763-w · Cited by 90
Zietek, T., Giesbertz, P., Ewers, M., Reichart, F., Weinmüller, M., Urbauer, E., Haller, D., Demir, I. E., Ceyhan, G. O., Kessler, H., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.577656 · Cited by 91
In silico Methods for Identification of Potential Therapeutic Targets
Zhang, X., Wu, F., Yang, N., Zhan, X., Liao, J., Mai, S., & Huang, Z. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00491-y · Cited by 114
“An analysis of AstraZeneca’s drug research and development programs showed that 82% of program terminations in preclinical studies were due to safety issues, of which 25% were target-related [2].”
MethodHuman organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
Wang, D., Villenave, R., Stokar‐Regenscheit, N., & Clevers, H. C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01317-y · Cited by 129
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Lauschke, V., & Ingelman-Sundberg, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101714 · Cited by 88
Assessing Toxicity with Human Cell-Based In Vitro Methods
Zink, D., Chuah, J. K. C., & Ying, J. Y. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.008 · Cited by 100
Miniproteins as a Powerful Modality in Drug Development
Crook, Z. R., Nairn, N. W., & Olson, J. M. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.12.008 · Cited by 91
Progesterone neuroprotection: The background of clinical trial failure
Schumacher, M., Denier, C., Oudinet, J., Adams, D., & Guennoun, R. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.11.010 · Cited by 98
Chen, H., Chen, X., Li, W., & Shen, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.27 · Cited by 86
Richardson, T. G., Hemani, G., Gaunt, T. R., Relton, C. L., & Davey Smith, G. (2020) · Nature Communications · doi:10.1038/s41467-019-13921-9 · Cited by 82
Zhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Bespalov, A., Steckler, T., Altevogt, B., Koustova, E., Skolnick, P., Deaver, D., Millan, M. J., Bastlund, J. F., Doller, D., Witkin, J., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.88 · Cited by 84
Bröske, A.-M. E., Korfi, K., Belousov, A., Wilson, S., Ooi, C.-H., Bolen, C. R., Cañamero, M., Alcaide, E. G., James, I., Piccione, E. C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005954 · Cited by 101
“Assessment of pharmacodynamic and response-associated biomarkers is essential in early clinical development enabling a deeper understanding of the mechanism of action, dose optimization and ultimately improving the overall success rate of clinical trials.(27)”
The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective
Garbaccio, R. M., & Parmee, E. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.11.011 · Cited by 81
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Silva, M. C., & Haggarty, S. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 83
Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 81
Luo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 92
A decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 90
Thomas, D., Cunningham, N. J., Shenoy, S., & Wu, J. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab115 · Cited by 90
“In clinical drug development and safety evaluations, adverse cardiac events have been a major cause for preclinical safety closures.(21) iPSC-CMs are an excellent platform to predict adverse effects such as the risk of QT prolongation or the involvement of cardiac ion channels in evaluating cellular arrhythmias.”
BackgroundAn improved model for fragment-based lead generation at AstraZeneca
Fuller, N. O., Spadola, L., Cowen, S. D., Patel, J. S., Schönherr, H., Cao, Q., McKenzie, A. R., Edfeldt, F., Rabow, A., & Goodnow, R. A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.023 · Cited by 81
Osteoarthritis Pathophysiology
Vincent, T. L., Alliston, T. N., Kapoor, M., Loeser, R. F., Troeberg, L., & Little, C. B. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.11.015 · Cited by 91
Importance of Quantifying Drug-Target Engagement in Cells
Stefaniak, J., & Huber, K. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00570 · Cited by 83
Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging
Swales, J. G., Dexter, A., Hamm, G. R., Nilsson, A., Strittmatter, N., Michopoulos, F., Hardy, C., Gutierrez, P. M., Mellor, M. J., Andrén, P. E., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b05239 · Cited by 77
Executable cancer models: successes and challenges
Clarke, M. A., & Fisher, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0258-x · Cited by 88
Ewart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D. J., Geys, H., Jarvis, P., Ju, H., Leishman, D., Leong, L., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu198 · Cited by 77
“Nonclinical and clinical safety-related terminations together contribute substantially to the overall attrition within drug development (Cook et al., 2014; Kola and Landis, 2004).”
BackgroundPeters, M. F., Choy, A. L., Pin, C., Leishman, D. J., Moisan, A., Ewart, L., Guzzie-Peck, P. J., Sura, R., Keller, D. A., Scott, C. W., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc01107b · Cited by 76
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond
Koola, M. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113409 · Cited by 85
An effector index to predict target genes at GWAS loci
Forgetta, V., Jiang, L., Vulpescu, N. A., Hogan, M. S., Chen, S., Morris, J. A., Grinek, S., Benner, C., Jang, D., Hoang, Q., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02434-z · Cited by 79
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 85
Machine Learning guided early drug discovery of small molecules
Pillai, N., Dasgupta, A., Sudsakorn, S., Fretland, J., & Mavroudis, P. D. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.017 · Cited by 85
Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond
Iqbal, J., Abbasi, B. A., Ahmad, R., Mahmood, T., Ali, B., Khalil, A. T., Kanwal, S., Shah, S. A., Alam, M. M., Badshah, H., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9352-3 · Cited by 82
Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS
Pachamuthu, K., Liu, Y., Aduda, V., Akare, S., Alam, R., Andreucci, A., Boulay, D., Bowman, K., Byrne, M., Cannon, M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac037 · Cited by 79
“Achieving sufficient bioavailability and tissue exposure at the site of action to achieve the desired pharmacodynamic effect on the target is an important determinant for any drug discovery program (52), and this can be particularly challenging in CNS (53).”
Spruill, M. L., Maletić‐Savatić, M., Martin, H., Li, F., & Liu, X. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115080 · Cited by 81
Cellular Biomechanics in Drug Screening and Evaluation: Mechanopharmacology
Krishnan, R., Park, J., Seow, C. Y., Lee, P. V. S., & Stewart, A. G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.005 · Cited by 81
“A review of the portfolio performance of AstraZeneca in Phase IIa and IIb studies from 2005 to 2010 suggested that 57% and 88%, respectively, of the project closures at this stage were due to a failure of efficacy, whereas attrition due to lack of efficacy in the preclinical phase was as low as 6% [1].”
eMolTox: prediction of molecular toxicity with confidence
Ji, C., Svensson, F., Zoufir, A., & Bender, A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty135 · Cited by 73
Watt, G. F., Scott-Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 70
“PK/PD relationships are the cornerstone of drug discovery and development [22] enabling the translation of these molecules into the clinic to explore their human pharmacology and aiding the reduction of drug attrition rates [23,24].”
Background
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.